ODAC gives a big thumbs-down to On­copep­tides' dan­gling ac­cel­er­at­ed ap­proval in mul­ti­ple myelo­ma

ODAC on Thurs­day vot­ed over­whelm­ing­ly against keep­ing the ac­cel­er­at­ed ap­proval for On­copep­tides’ Pepax­to, 14 vot­ing “no,” and 2 “yes” to the FDA’s ques­tion of: “Is …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER